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Glynn RJ1,Avorn J1
1Brigham and Women’s Hospital / Harvard Medical School,
Boston, MA, USA; 2Harvard School of Public Health, Boston,
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Noncompliance with statins is common in typical patient
care settings, yet population-level beneﬁts and cost-
effectiveness have been estimated based on clinical trials,
where medication compliance is high. 
OBJECTIVES: To evaluate 1) the excess morbidity and
mortality attributable to noncompliance, and 2) the 
cost-effectiveness of statins under conditions of typical
compliance. 
METHODS: A Markov model was used to compare 
three scenarios of compliance with statin therapy (ideal,
typical, and no treatment) in a hypothetical cohort of
patients 65 to 84 years of age with a history of myocar-
dial infarction (MI). Outcomes were compared incre-
mentally among the scenarios and included lifetime risk
of reinfarction and stroke, quality-adjusted life-years
(QALYs) gained, lifetime costs in U.S. dollars, and 
cost-effectiveness (cost per QALY gained). Data for the
no treatment and ideal compliance scenarios were based
on the placebo and treatment arms of the Cholesterol And
Recurrent Events (CARE) trial, respectively. Data for the
typical compliance scenario were based on a sub-study 
of actual ﬁlled prescriptions in 1035 patients similar to
CARE participants, with effectiveness for this group
interpolated from the no treatment and ideal compliance
groups. 
RESULTS: Compared with no treatment, typical com-
pliance with statins yielded an average of 0.15 additional
QALY; ideal compliance would have gained 0.38 QALY.
For 1000 patients with typical compliance, 52 myocar-
dial infarctions and 26 strokes were attributable to non-
compliance. Compared to no treatment, the incremental
cost-effectiveness of secondary prevention with statins in
patients 65–84 years of age with typical compliance was
$14,800 per QALY gained. 
CONCLUSIONS: A typical elderly population using
statins for secondary prevention can be expected to
receive less than 40% of the potential beneﬁts of therapy.
Despite the lost clinical beneﬁts, statin therapy remains
relatively cost-effective, even when compliance is modest.
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OUTCOMES AND COSTS OF ISCHEMIC
COMPLICATIONS AND BLEEDING IN PATIENTS
UNDERGOING PERCUTANEOUS CORONARY
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Delea TE1, Plent S2, Edelsberg JS1, Oster G1
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Cambridge, MA, USA
OBJECTIVE: The incidence of ischemic complications
and bleeding among patients undergoing percutaneous
coronary interventions (PCIs) in clinical trials is well 
documented. Little is known about outcomes and costs
of these events in typical clinical practice however. 
METHODS: Data were obtained from a clinical and
administrative database containing information for
patients admitted to >100 geographically diverse US
acute-care hospitals (MQ-Proﬁle, Cardinal Information
Corporation, Marlborough, MA). The study sample con-
sisted all patients who underwent PCI from 7/98–6/99.
Measures included length of stay (LOS), hospital costs,
and in-hospital mortality, and were compared for patients
with vs. without ischemic complications (myocardial
infarction [MI], coronary artery bypass graft [CABG]
surgery, repeat PCI) or bleeding (major, minor) using
accelerated failure-time models for LOS and costs and
logistic regression for mortality. 
RESULTS: The sample included 5,326 PCI patients; 
mean age was 64 years; 63% were male. The incidence
of ischemic complications was 9.9% (2.9% MI, 1.4%
CABG, 5.6% repeat PCI); 11.5% experienced bleeding
(without ischemic complications) (5.9% major, 5.6%
minor). Adjusted LOS and costs in those without ischemic
complications or bleeding (n = 4,183) averaged 3.2 days
and $9,696; mortality was 1.6%. MI (n = 156), CABG
(n = 77), and repeat PCI (n = 299) patients had an
adjusted LOS of 4.1, 11.7 and 6.5 days respectively; costs
averaged $11,370, $29,470, and $18,765 (p < .001 for
all comparisons vs. no complications). Corresponding
odds ratios (ORs) for mortality were 2.8 (p = .037), 3.7
(p = .007), and 1.4 (p = .338). In patients with major
bleeding (n = 315), adjusted LOS and costs averaged 6.2
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